Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Anticoagulant: the invisible yet essential ally of therapeutic apheresis
At first glance, one might think it’s normal saline.
Pearling drops, a steady flow, almost reassuring. And yet… what you’re seeing is far more than a simple solution.
It is an anticoagulant, a fundamental pillar of therapeutic apheresis procedures: ACD-A (Acid Citrate Dextrose – Solution A).
Its mission is clear and essential: to prevent blood from clotting in the extracorporeal circuit during apheresis.
Without it, safe blood processing would simply not be possible.
In practice, anticoagulation ratios can be adjusted depending on the procedure. But not all procedures are equal in terms of duration.
Plasma exchange or red cell exchange typically last 1 to 2 hours.
However, during hematopoietic stem cell collections or lymphocyte collections for CAR-T cell manufacturing, patients may remain connected to the machine for 3 to 6 hours, sometimes processing up to three mass of total blood volumes to achieve the required cell yield.
The specificity of ACD-A?
Citrate chelates calcium, which may lead to hypocalcemia: perioral tingling, metallic taste, chills, tremors… and potentially more severe symptoms if not anticipated.
This is why true expertise in apheresis is essential.
Optimizing a procedure means finding the right balance between collection efficiency, clinical safety, and patient comfort.
It requires close collaboration between nurses, physicians… and industry partners.
Because in apheresis, every single drop matters.”
Stay updated with Hemostasis Today.
-
May 8, 2026, 13:59Jessica Garcia: Clinic Gave Me All the Feelings Today
-
May 8, 2026, 13:06Paula Dibo: New Evidence Connecting Anti PLA2R Antibodies and Thrombosis Risk
-
May 8, 2026, 12:58Ashutosh Kumar Pandey: IVC Filters Are Not a ‘Treatment’ for DVT
-
May 8, 2026, 12:57Aamir Saeed: Identifying Risk Factors for Bleeding After ERCP and Sphincterotomy
-
May 8, 2026, 12:42Alyaa Al-Mughairy: First Pediatric Case of Successful DOAC Treatment in a Clinical Setting
-
May 8, 2026, 09:25Athma Dias: Limitations of PT and APTT in Predicting Thrombotic Risk
-
May 8, 2026, 09:12Abhishek Kumar: New Horizons in Hemophilia B Treatment and Prevention
-
May 8, 2026, 08:19Augustina Isioma Ikusemoro: Thalassaemia is not Just a Blood Disorder – It is a Public Health Priority
-
May 8, 2026, 06:24Transforming Thrombosis Management With Antithrombotic Stewardship – Anticoagulation Forum